Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis

References

• Caviglia GP, Abate ML, Pellicano R, et al. Chronic hepatitis B therapy: available drugs and treatment guidelines. Minerva Gastroenterol Dietol. 2015;61:61–70.
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer J, Asch SM, et al. Risk of hepatocellular cancer in HCV patients treated with direct acting antiviral agents. Gastroenterology. 2017;153:996–1005.
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver, European Organization For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.
   PubMed Web of Science ®Google Scholar
• Lombardi A, Grimaldi A, Zappavigna S, et al. Hepatocarcinoma: genetic and epigenetic features. Minerva Gastroenterol Dietol. 2018;64:14–27.
   PubMed Web of Science ®Google Scholar
• Li C, Zhang Z, Zhang P, et al. Diagnostic accuracy of des-gamma-carboxy prothombin vesrus α-fetoprotein for hepatocellular carcinoma: a systematic review. Hepatol Res. 2014;44:E11–E25.
   PubMed Web of Science ®Google Scholar
• Petrini E, Caviglia GP, Abate ML, et al. MicroRNAs in HBV-related hepatocellular carcinoma: functions and potential clinical applications. Panminerva Med. 2015;57:201–209.
   PubMed Web of Science ®Google Scholar
• Jia H, Yu H, Liu Q. Single nucleotide polymorphisms of MIR-149 gene rs2292832 contributes to the risk of hepatocellular carcinoma, but not overall cancer: a meta-analysis. Minerva Med. 2016;107:259–269.
   PubMed Web of Science ®Google Scholar
• Abenavoli L, Boccuto L. New serum markers for detection of early hepatocellular carcinoma. Panminerva Med. 2017;59:281–282.
   PubMed Web of Science ®Google Scholar
• Liebman HA, Furie BC, Tong MJ, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310:1427–1431.
   PubMed Web of Science ®Google Scholar
• Baek YH, Lee JH, Jang JS, et al. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology. 2009;56:763–767.
   PubMedGoogle Scholar
• Shirabe K, Itoh S, Yoshizumi T, et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol. 2007;95:235–240.
   PubMed Web of Science ®Google Scholar
• Kim DY, Paik YH, Ahn SH, et al. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology. 2007;72:52–57.
   PubMed Web of Science ®Google Scholar
• Arii S, Sata M, Sakamoto M, et al. Management of hepatocellular carcinoma: report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:667–685.
   PubMed Web of Science ®Google Scholar
• Van Hees S, Michielsen P, Vanwolleghem T. Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2016;22:8271–8282.
   PubMed Web of Science ®Google Scholar
• Song PP, Xia JF, Inagaki Y, et al. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol. 2016;22:262–274.
   PubMed Web of Science ®Google Scholar
• Choi J, Park Y, Kim JH, et al. Evaluation of automated serum des-gamma-carboxyprothrombin (DCP) assays for detecting hepatocellular carcinoma. Clin Biochem. 2011;44:1464–1468.
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012.
   PubMed Web of Science ®Google Scholar
• Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.
   PubMedGoogle Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
   PubMed Web of Science ®Google Scholar
• Poté N, Cauchy F, Albuquerque M, et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol. 2015;62:848–854.
   PubMed Web of Science ®Google Scholar
• Yu R, Ding S, Tan W, et al. Performance of protein induced by vitamin K absence or antagonist-II (PIVKA-II) for hepatocellular carcinoma screening in Chinese population. Hepat Mon. 2015;15:e28806.
   PubMed Web of Science ®Google Scholar
• Viggiani V, Palombi S, Gennarini G, et al. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients. Scand J Gastroenterol. 2016;51:1257–1262.
   PubMed Web of Science ®Google Scholar
• Sultanik P, Ginguay A, Vandame J, et al. Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse® G600 analyzer. J Viral Hepat. 2017;24:80–85.
   PubMed Web of Science ®Google Scholar
• Ji J, Wang H, Li Y, et al. Diagnostic evaluation of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatitis B virus-related hepatocellular carcinoma in China: a large-scale, multicentre study. PLoS One. 2016;11:e0153227.
   PubMed Web of Science ®Google Scholar
• Yu R, Xiang X, Tan Z, et al. Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients. Sci Rep. 2016;6:35050.
   PubMed Web of Science ®Google Scholar
• Huang S, Jiang F, Wang Y, et al. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients. Tumour Biol. 2017;39. DOI:10.1177/1010428317705763
   Google Scholar
• Saitta C, Raffa G, Alibrandi A, et al. PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients. Medicine. 2017;96:e7266.
   PubMed Web of Science ®Google Scholar
• Caviglia GP, Abate ML, Gaia S, et al. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II. Panminerva Med. 2017;59:283–289.
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Scotto R, et al. Diagnostic accuracy of PIVKA-II, alpha-fetoprotein and a combination of both in diagnosis of hepatocellular carcinoma in patients affected by chronic HCV infection. In Vivo. 2017;31:695–700.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang W, Liu Y, et al. Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma. Infect Agents Cancer. 2017;12:47.
   PubMed Web of Science ®Google Scholar
• Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835–853.
   PubMed Web of Science ®Google Scholar
• Hu B, Tian X, Sun J, et al. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis. Int J Mol Sci. 2013;14:23559–23580.
   PubMed Web of Science ®Google Scholar
• Tateishi R, Yoshida H, Matsuyama Y, et al. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int. 2008;2:17–30.
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317–370.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Kanwal F, Davila JA, et al. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology. 2014;146:1249–1255.
   PubMed Web of Science ®Google Scholar
• Lou J, Zhang L, Lv S, et al. Biomarkers for hepatocellular carcinoma. Biomark Cancer. 2017;9:1.
   PubMedGoogle Scholar
• Fouad YM, Mohamed HI, Kamal EM, et al. Clinical significance and diagnostic value of serum dickkopf-1 in patients with hepatocellular carcinoma. Scand J Gastroenterol. 2016;51:1133–1137.
   PubMed Web of Science ®Google Scholar
• Lim TS, Kim DY, Han KH, et al. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scand J Gastroenterol. 2016;51:344–353.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Nouso K, Sakaguchi K, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol. 2006;101:2038–2043.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev. 2014;23:144–153.
   PubMed Web of Science ®Google Scholar
• Caviglia GP, Abate ML, Petrini E, et al. Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection. Hepatol Res. 2016;46:E130–E135.
   PubMed Web of Science ®Google Scholar
• Feier D, Lupsor Platon M, Stefanescu H, et al. Transient elastography for the detection of hepatocellular carcinoma in viral C liver cirrhosis. Is there something else than increased liver stiffness? J Gastrointestin Liver Dis. 2013;22:283–289.
   PubMed Web of Science ®Google Scholar
• Attallah AM, Omran MM, Attallah AA, et al. HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Br J Cancer. 2013;109:1657–1665.
   PubMed Web of Science ®Google Scholar
• El-mezayen HA, Darwish H. Development of a novel score for early detection of hepatocellular carcinoma among high-risk hepatitis C virus patients. Tumour Biol. 2014;35:6501–6509.
   PubMedGoogle Scholar
• Berhane S, Johnson PJ, Tada T, et al. Serial changes in serum biomarkers (GALAD model) prior to detection of HCC by ultrasound surveillance; application of statistical process control methodology. J Hepatol. 2017;66:S628.
   Web of Science ®Google Scholar
• Schütte K, Schulz C, Link A, et al. Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol. 2015;7:139–149.
   PubMed Web of Science ®Google Scholar